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Abstract Although elucidation of the medicinal chemistry
of agonists and antagonists of the P2Y receptors has lagged
behind that of many other members of group A G protein-
coupled receptors, detailed qualitative and quantitative
structure–activity relationships (SARs) were recently con-
structed for several of the subtypes. Agonists selective for
P2Y1, P2Y2, and P2Y6 receptors and nucleotide antagonists
selective for P2Y1 and P2Y12 receptors are now known.
Selective nonnucleotide antagonists were reported for
P2Y1,P 2 Y 2, P2Y6,P 2 Y 11, P2Y12, and P2Y13 receptors.
At the P2Y1 and P2Y12 receptors, nucleotide agonists (5′-
diphosphate derivatives) were converted into antagonists of
nanomolar affinity by altering the phosphate moieties, with
a focus particularly on the ribose conformation and
substitution pattern. Nucleotide analogues with conforma-
tionally constrained ribose-like rings were introduced as
selective receptor probes for P2Y1 and P2Y6 receptors.
Screening chemically diverse compound libraries has begun
to yield new lead compounds for the development of P2Y
receptor antagonists, such as competitive P2Y12 receptor
antagonists with antithrombotic activity. Selective agonists
for the P2Y4, P2Y11, and P2Y13 receptors and selective
antagonists for P2Y4 and P2Y14 receptors have not yet been
identified. The P2Y14 receptor appears to be the most
restrictive of the class with respect to modification of the
nucleobase, ribose, and phosphate moieties. The continuing
process of ligand design for the P2Y receptors will aid in
the identification of new clinical targets.
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Introduction
The P2Y receptors are 7TM (containing seven transmem-
brane domains) receptors that couple to G protein-dependent
and -independent signaling pathways, including ion chan-
nels [1]. Eight human subtypes of the P2Y receptor family
have been defined. According to a dendrogram relating
sequence homology, the P2Y1, P2Y2, P2Y4,P 2 Y 6, and
P2Y11 receptors form a cluster of preferentially Gq-coupled
receptors, and the P2Y12, P2Y13, and P2Y14 receptors form
a cluster of preferentially Gi-coupled receptors [2, 3].
Elucidation of the medicinal chemistry of agonists and
antagonists of the P2Y receptors has lagged behind
characterization of many other members of the group A G
protein-coupled receptors (GPCRs) [4–8]. Many of the
early ligands suffered from promiscuity, affecting not only
multiple P2Y metabotropic receptors but also P2X nucle-
otide-gated ion channels, various enzymes involved in
controlling levels of extracellular nucleotides and nucleo-
sides, and intracellular signaling pathways. However, the
armamentarium of P2Y receptor ligands available has
recently expanded greatly in both quantity and quality.
Qualitative and quantitative structure–activity relationships
(SARs) were recently constructed in detail for nucleotides
acting at P2Y1 and P2Y12 receptors and with less detail for
the P2Y2 and P2Y6 receptors. Molecular modeling of these
receptors and docked ligands with a rhodopsin-based
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radioligand binding have been successful at only a few of
the P2Y receptors. In this review, we identify the most
selective molecular probes reported for the P2Y receptors,
which have enabled pharmacological studies in the nucle-
otide field. The availability of pharmacological tools for the
various subtypes (along with genetically modified mouse
strains) is also enabling biological studies.
The five major native ligands of the P2Y receptors (Fig. 1)
are adenosine 5′-triphosphate (ATP) 1, adenosine 5′-
diphosphate (ADP) 2, uridine 5′-triphosphate (UTP) 3,
uridine 5′-diphosphate (UDP) 4, and UDP-glucose 5 (or
other UDP sugars). Dinucleotides such as Ap4U 6 are also
naturally occurring P2Y agonists [9]. Adenosine mono-
phosphate (AMP) and uridine monophosphate (UMP) are
inactive at P2Y receptors. Figure 2 shows the correspon-
dence of these nucleotides and the subtypes that they activate
or antagonize, along with the diversity of representative
biological effects induced by P2Y receptor activation. Some
single nucleotides activate multiple subtypes (e.g., ATP and
UTP) or activate one subtype and antagonize another (e.g.,
ATP and UDP). UDP acts as a competitive antagonist at the
human but not rat P2Y14 receptor [10].
Pharmacological studies of P2Y receptors are compli-
cated by the presence of ectonucleotidases that degrade the
native agonist and antagonist nucleotides. Products of the
enzymatic hydrolysis might either be inactive or have
activity at other P2Y receptor subtypes (e.g., 5′-triphos-
phate derivatives are converted to diphosphates) or at
adenosine receptors (when adenosine is produced by the
action of CD73/5′-nucleotidase on AMP [11]). Alternately,
the 5′-diphosphates might be phosphorylated to biologically
active 5′-triphosphates by the action of nucleoside diphos-
phokinase [12]. Thus, the state of activation of multiple
P2Y receptors in a given tissue is a complex function of the
kinetics of release, interconversion, and inactivation of the
family of receptor-interactive nucleotides.
Various phosphate modifications, such as a terminal
thiophosphate substitution, increase stability toward nucle-
otidases. Thus, ATPγS 7, ADPβS 8,U T P γS 9,a n d
UDPβS 10 have been used to activate P2Y receptors, as
noted in Table 1. The terminal thiophosphates are generally
well tolerated in the nucleotide-binding sites of the P2Y
receptors. However, these compounds are susceptible to
oxidation and are difficult to synthesize on a large scale.
Thiophosphate substitutions at nonterminal phosphate
groups are better tolerated at the P2Y1 than at the P2Y2
and P2Y4 subtypes [15, 16]. Another type of modification
that increases the stability of such nucleotide derivatives is
replacement of a bridging oxygen of the phosphate chain
with methylene or dihalomethylene; however, this modifi-
cation tends to reduce potency at the P2Y receptors [17].
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Fig. 1 a Naturally occurring P2Y receptor agonists and terminally thiophosphate-substituted analogues. b Structures of adenine-derived
nucleotide agonists of P2Y1, P2Y12, and P2Y13 receptors
76 Purinergic Signalling (2009) 5:75–89The P2Y receptor agonists are nearly exclusively
nucleotide derivatives, which presents barriers to drug
development because of their instability, low bioavailabil-
ity, nonspecific binding to biological membranes, and
tedious synthesis, purification, and structural verification.
Screening of small-molecule ligands of diverse structure
has not yet been carried out extensively for the P2Y family.
Radioligand binding is effective for ligand screening in
many other GPCRs, but biological assays at the P2Y
receptors usually exploit functional endpoints, e.g., typical-
ly Gq-stimulated phospholipase C-β for the P2Y1-like
subfamily (Table 1). Suitable radioligand-binding methods
are only available for the P2Y1 and P2Y12 receptors [18,
19]; those methods were developed after many attempts to
use radiolabeled nucleotides were reported in the literature
and later proved unsatisfactory.
Adenine nucleotide-responsive P2Y receptors
SAR of P2Y1, P2Y12, and P2Y13 receptors
for 5′-diphosphates
The most prominent regions of distribution of these ADP-
responsive receptors are P2Y1 (platelets, endothelial cells,
brain), P2Y12 (platelets, brain), and P2Y13 (immune
system, dendritic cells). There is no striking sequence
homology between the P2Y1 receptor and P2Y12 or P2Y13
receptors. The sequence identity of the TM domains of the
human P2Y1 is 26.9% and 28.0% for the P2Y12 and P2Y13
receptors, respectively. In contrast, the sequence identity
within the TM domains of the P2Y12 and P2Y13 receptors
is 57.0%.
Modification of the phosphate moiety ADP2 is the principal
endogenous agonist at the P2Y1,P 2 Y 12,a n dP 2 Y 13
receptors. ATP 1 interacts with less affinity and efficacy
than ADP at the P2Y1 and P2Y12 receptors. At P2Y12
receptors, the loss of efficacy is pronounced, such that ATP
and other 5′-triphosphate derivatives act as antagonists. At
P2Y13 receptors, ADP and ATP both act as full agonists.
Modifications of the di- and triphosphate moieties of the
nucleotide ligands have been probed for effects on P2Y
receptor activity (Fig. 1). For example, when an ionizable
oxygen of the α-phosphate of the triphosphate moiety of
adenine nucleotide derivatives is substituted with a BH2
moiety, it favors P2Y1 receptor potency [20]. Thus, the
P2Y1 receptor can be activated by a 5′-(1-boranotriphos-
phate) derivative 14 of 2-methylthio-ATP 11. Separation of
two stable isomers of 14 demonstrated stereoselectivity in
activation of the rat P2Y1 receptor (EC50=2.6 nM, for the
more potent R-isomer of 14).
Fig. 2 Correspondence of the five principal native ligands of the human P2Y receptors and the subtypes they activate. Note that various
dinucleotides also activate P2Y receptors. For example, dinucleoside triphosphates activate the P2Y6 receptor
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adenine moiety of the nucleotides has been extensively
explored at the P2Y1 and P2Y12 receptors. Broad freedom
of substitution has been observed at the C2 position, and
sterically bulky groups and extended chains at this position
are often tolerated in receptor binding.
A small hydrophobic pocket in the receptor-binding site
surrounds the N
6-position of adenine nucleotides acting as
P2Y1 agonists and antagonists [21], and the P2Y12 receptor
has a considerably larger pocket [22]. Amino, ether, and
thioether derivatives at the 2-position of the adenine ring of
ATP were compared in P2Y1 potency; thioethers, in
general, are the most potent [23].
2-Alkylthio and 2-(arylalkylthio) ethers of ADP are highly
potent agonists at these subtypes (Fig. 1b) [24, 25]. 2-
Methylthio-ADP 12 is a potent agonist (EC50 in nM) at
human P2Y1 (3), rat P2Y12 (1), and human P2Y13 (1)
receptors [2, 7, 26]. 2-Methylthio (2-MeS)-ATP 11 is less
potent (EC50=8 nM) than 12 at the P2Y1 receptor and also
less selective because certain P2X receptors are activated [26].
A 2-[2-(4-aminophenylethyl)] 5′-triphosphate derivative 15
exhibits an EC50 of 1 nM at the P2Y1 receptor, and a related
azido 5′-diphosphate derivative 16 serves as a photoaffinity
label of P2Y receptors in platelets [27]. 2-Alkynyl substitu-
ents on adenine nucleotide analogues provide high potency as
either P2Y1/12 receptor agonists or antagonists [28].
Table 1 Potencies and selectivities of natural and synthetic ligands at the human P2Y receptors (references in brackets)
Subfamily and
Pharmacologic
Characteristics
Receptor
Subtype
Ligands (potency and selectivity)
Native
agonist
pEC50
(ref)
Synthetic
agonist
pEC50
(ref)
Cross
reactivity
Synthetic (or
native)
antagonist
pEC50 (ref) Cross reactivity
P2Y1-like,
Gq-coupled
P2Y1 ADP 2 5.09 [6] MeSADP 12 8.22 [6] P2Y12,13 A3P5P 25 6.08 [35] none
ADP-β-S
a 8 7.02 [6] P2Y12,13 MRS2179 26 6.48 [36] none
MRS2365 24 9.40 [34] none MRS2279 29 7.28 [6] none
MRS2500 30 9.02 [39] none
P2Y2 UTP 3 8.10 [4] UTP-γ-S
a 9 6.62 [4] none Suramin 48a 4.32 [6] P2Y11
ATP 1 7.07 [4] NS365 68c 7.00 [4] P2Y4 AR-C126313 52 6[ 4,74]
INS37217 69 6.66 [4] P2Y4 MRS2576
b 57 4.04 [81] P2Y1,4,6
MRS269863b 8.10 [64] none
P2Y4 UTP 4 5.60 [6] 2'-azido-dUTP 64 7.14 [12] P2Y4 PPADS 49 < 5.00 [6] P2Y2
ATP 1 4.37 [6] various (ago), P2Y12
MRS2577
b 56 4.01 [81] P2Y6
P2Y6 UDP 4 6.52 [6] UDP-β-S 10 7.33 [4] none MRS2578
b 55 7.43 [4] none
INS48823 71 6.90 [4] none
MRS2633 67 6.64 [68] none
MRS2693 66 7.83 [68] None
P2Y11 ATP 1 4.77 [6] AR-C67085 35 5.05 [50] P2Y12,13
(ant)
Suramin 48a 4.79 [6] P2Y2
ATP-γ-S
a 7 5.52 [6] P2Y1,2,12 AMP-α-S
a 18 partial agonist
[50]
none
P2Y1-like,
Gi-coupled
P2Y12 ADP 2 7.22 [1] MeSADP 12 7.85 [1] P2Y1,13 MeSAMP 13 4.00 [82] none
ADP-β-S
a 8 6.72 [1] P2Y1,13 ATP 1 3.60 [40] various (ago), P2Y4
AR-C67085 36 4.52 [45] P2Y11 (ago), P2Y13
AR-C69931MX 37 9.40 [40] P2Y11 (ago), P2Y13
AZD6140 38 7.90 [45] none
INS50589 40 7.80 [41] none
Clopidogrel
c 41 5.74 [42] none
P2Y13 ADP 2 7.94 [84] MeSADP 12 7.85 [84] P2Y1,12 MRS2211 50 5.97 [83] none
AR-C67085 36 6.67 [50] P2Y11 (ago), P2Y12
AR-C69931MX 37 8.40 [83] P2Y11 (ago), P2Y13
P2Y14 UDP-glucose 75 6.45 [71] MRS2690 78 7.31 [71] none UDP 4 7.28 [10] P2Y6 (ago)
UDP-galactose 76 6.17 [71]
UDP-glucosamine 77 5.36 [71]
a, unstable to oxidation.
b, an insurmountable antagonist, which is hydrophobic and reactive toward nucleophiles and aqueous medium.
c, active only in vivo, through a thiol-reactive metabolite.
ago, agonist; ant, antagonist
78 Purinergic Signalling (2009) 5:75–89Although AMP is inactive at the P2Y1 receptor, adding a
2-thioether substituent as a receptor “anchor” allows aden-
osine 5′-monophosphate analogues to bind to and activate
the P2Y1 receptor. Among these derivatives, 2-(hexylthio)
(HT)-AMP 17 is especially potent, with an EC50 of 59 nM at
the turkey P2Y1 receptor [29]. 2-MeS-AMP 13 weakly
activates the P2Y1 receptor but also acts as a weak antagonist
of the P2Y12 receptor [30]. α-Thio ATP derivatives, such as
compound 18, are potent P2Y1 receptor agonists (EC50=
17 nM). The corresponding α-thio AMP derivatives are
weak as P2Y receptor agonists, but the simultaneous
inhibition of ATP diphosphohydrolase [ecto-apyrase nucleo-
side triphosphate diphosphohydrolase-1 (NTPDase1) or
CD39, present in blood, neuronal, endothelial, pancreatic,
and smooth muscle cells [31]] complicates their use as
pharmacological probes [15].
Limited alteration of the heterocyclic ring of P2Y-active
nucleotides is possible. 8-Aza and 1-deaza modifications
are generally tolerated at P2Y1 and P2Y12 receptors [22, 34,
87], but other modifications, such as N1, N6-etheno, result
in inactivity at P2Y receptors [32]. A fluorescent derivative
of ATP 19 containing a tricyclic nucleobase is strikingly
potent in activation of the P2Y1 receptor [33].
Modification of the ribose moiety Replacement of the
ribose 2′ and/or 3′ hydroxyl groups with H in adenine
nucleotide agonists greatly reduces the potency at P2Y1
receptors. A 1,5-anhydrohexitol bisphosphate derivative 20
activates the P2Y1 receptor (EC50=6.29 μM at turkey P2Y1
receptor) [34] (Fig. 1b).
Simple carbocyclic (cyclopentyl) analogues of ATP en-
hance antagonist affinity at the P2Y12 receptor [22]. Among
the more successful examples of the use of carbocyclic or
sterically constrained carbocyclic substitution of the ribose
moiety for P2Y receptor interactions are the bicyclic
“methanocarba” analogues [35, 36]. Two isomeric forms of
the methanocarba (bicyclo[3.1.0]hexane) ring system have
been used as ribose replacements in ATP, representing a
North (N), 2′-exo envelope 21 or South (S), 2′-endo envelope
22 conformation. The addition of a 2-MeS group to 21 to
form 24 provides a highly potent and selective P2Y1 agonist,
MRS2365 (EC50=0.40 nM) [37]. Unlike 2MeS-ADP, this
compound does not activate P2Y12 or P2Y13 receptors [38].
(N)-methanocarba derivative 23 is a full agonist at the P2Y1
receptor (EC50=158 nM); the corresponding 9-riboside, β,γ-
methylene-ATP, is a partial weak agonist at that subtype.
A successful approach to designing potent and selective
P2Y1 receptor antagonists became possible with the observa-
tion by Boyer et al. that naturally occurring adenosine
bisphosphate derivatives such as A3P5P 25 (Fig. 3a) act as
partial agonists or antagonists of the receptor (EC50=
0.83 μM) [39]. This has led to improved 2′-deoxyribose
3′,5′-bisphosphate derivatives MRS2179 26 (EC50=0.33μM)
and MRS2216 27 (EC50=0.21 μM), which are potent and
selective P2Y1 receptor antagonists [34]. A C-nucleotide-
based antagonist 28 of the P2Y1 receptor is patterned after
MRS2179 [40]. (N)-methanocarba substitution within the
family of bisphosphate antagonists yields MRS2279 29 and
MRS2500 30, which display nanomolar potency at the P2Y1
receptor (EC50=52 nM and 0.95 nM, respectively) [18].
Moderate antagonist activity at the P2Y1 receptor is retained
after removal of the 5′-phosphate group of MRS2500 in 31
(EC50=1560 nM) [41].
Acyclic bisphosphate antagonists of the P2Y1 receptor
and related derivatives 32–35 have been characterized [42,
43]. Short alkyl chains bearing two phosphate groups
attached at the adenine 9-position are favored over long
chains. The bisphosphate derivative MRS2298 32 is a
potent antagonist of the P2Y1 receptor (binding Ki=
29.6 nM, human). MRS2496 34 is a bisphosphonate
derivative, which remains tolerated in the P2Y1 receptor
binding site (binding Ki=76 nM, human). Compound 35,
which contains a cycloproyl ring within the 9-alkyl
subsituent, is a P2Y1 antagonist with micromolar affinity.
Although various phosphate derivatives of the adenine 9-
ribosides (cyclic) may be either agonists or antagonists of
the P2Y1 receptor, only antagonism has been achieved in
the acyclic series.
The observation that ATP analogues inhibit platelet
aggregation by antagonism of the P2Y12 receptor enabled
development of the 5′-triphosphate derivatives AR-C67085
(EC50=30 μM) 36 and AR-C69931MX 37 (Cangrelor,
EC50=0.4 nM) as antithrombotic agents, which were in
clinical testing [44] (Fig. 3b). Other nucleoside–nucleotide
derivatives were investigated for P2Y12 receptor antago-
nism [42, 45]. For example, AZD6140 38a is an uncharged
nucleoside-based antagonist of the P2Y12 receptor of high
potency (pIC50=7.9) that has been in clinical trials [22, 89].
A similar carbocyclic derivative 38b containing a 1H-
tetrazol-5-yl group was recently reported to bind to the
P2Y12 receptor with an IC50 value of 2 nM [87]. The
(1R,2S)-2-phenylcyclopropyl derivative 38b was found to
be 30-fold more potent than the corresponding (1S,2R)
isomer. The uncharged nucleoside derivative MRS2395 33
[2,2-dimethyl-propionic acid 3-(2-chloro-6-methylamino-
purin-9-yl)-2-(2,2-dimethyl-propionyloxymethyl)-propyl
ester] is a weak antagonist of the P2Y12 receptor [5]. The
ADP derivative INS49266 39 (EC50=0.052 μM) and the
AMP derivative INS50589 40 (EC50=0.011 μM) act as
potent competitive antagonists of the P2Y12 receptor [46].
Nonnucleotide antagonists of P2 receptors have also been
identified and modified to achieve P2Y12 receptor selectiv-
ity (Fig. 4). The clinical success of the thienopyridine
clopidogel 41 as an antithrombotic agent has stimulated the
development of other P2Y12 antagonists. The thienopyr-
idines act as liver-activated prodrugs that are irreversible
Purinergic Signalling (2009) 5:75–89 79inhibitors of the P2Y12 receptor [47]. Thiol 41b is reported
to be the active metabolite of clopidogrel. Prasugrel 42 is a
P2Y12 antagonist with similar action, which shows clinical
promise [48].
Competitive antagonists of P2Y12 receptors that do not
require chemical conversion to an active species in vivo and
that are nonnucleotides, i.e., not highly charged phosphate
derivatives, are also sought as antithrombotic agents [45].
Screening of compound libraries has aided hit-and-lead
identification in this effort. Compound 43 is a tricyclic
benzothiazolo[2,3-c]thiadiazine antagonist of the P2Y12
receptor (EC50=0.18 μM) [19]. Compound 44 is a
competitive P2Y12 receptor antagonist [49]. The directly
acting (i.e., not requiring chemical transformation in vivo
prior to interacting with the receptor) P2Y12 antagonist
BX677 45 exhibits a wider therapeutic index than does
clopidogrel in experimental models of thrombosis [50].
Other nonnucleotide heterocyclic derivatives have been
discovered that act as selective P2Y1 receptor antagonists
[51]. Recently, PRT128 (structure not disclosed) was
introduced as an orally active direct-acting and reversible
P2Y12 receptor antagonist [88].
Other classes of nonnucleotide antagonists of P2
receptors have also been identified and modified to achieve
P2Y receptor selectivity (Fig. 4). Derivatives of pyridoxal
phosphate, e.g., pyridoxal-phosphate-6-azophenyl-2′,4′-
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80 Purinergic Signalling (2009) 5:75–89disulfonate (PPADS) 49, are generally relatively nonselec-
tive antagonists of the P2Y1 receptor and other subtypes
[4]. The SAR of P2 receptor antagonists derived from
pyridoxal phosphate was reviewed by Lambrecht and
coworkers [52]. Pyridyl isatogen 51 antagonizes the P2Y1
receptor.
Recently, a nonnucleotide antagonist of the P2Y1
receptor 47 has been reported through chemical optimiza-
tion of a library hit [86]. This compound has a Ki value of
90 nM at the human P2Y1 receptor and is proposed for use
as an antithrombotic agent. It is orally bioavailable with a
half life in rats of 2.8 h.
A moderately selective antagonist of the P2Y13 receptor,
MRS2211 50, has been identified [53]. Nucleotide deriva-
tives AR-C67085 36 (EC50=4 nM) and AR-C69931MX 37
(EC50=213 nM) potently antagonize the P2Y13 receptor.
SAR of P2Y11 and P2Y2 receptors for 5′-triphosphates
P2Y11 receptor agonists
Ten years ago, the human P2Y11 receptor was cloned from
human placenta [54]. This P2Y receptor subtype is also
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amino acid identity with other P2Y receptors. The P2Y1
receptor is the closest homologue of the P2Y11 receptor
subtype, with 37.8% identity in the TM domains. The
amino acid identity of the TM domains of the P2Y11
receptor with the P2Y2 receptor is 35.2%. The P2Y11
receptor demonstrates the least homology (20%–22%) with
the P2Y12-like receptor subfamily.
As with the P2Y1 and P2Y2 receptors, the P2Y11 receptor
can be activated by adenosine 5′-triphosphate (ATP) 1,
which is its native agonist. ATP-induced activation of the
P2Y11 receptor stably expressed in CHO-K1 cells and in
1321N1 astrocytoma cells results in accumulation of both
cyclic AMP and IP3. These findings indicate that the P2Y11
receptor is coupled to both the adenylyl cyclase (via Gs)a n d
the phosphoinositide (via Gq)p a t h w a y s[ 54, 57].
It was suggested that nonadenine triphosphates, includ-
ing UTP 3, guanosine 5′-triphosphate (GTP), cytidine
5′-triphosphate (CTP), thymidine 5′-triphosphate (TTP),
inosine 5′-triphosphate (ITP), and UDP 4 are inactive at
the P2Y11 receptor [54, 57]. Another report characterized
UTP as a Ca
2+-mobilizing agonist in P2Y11 receptor-
expressing 1321N1 astrocytoma cells, whose potency and
maximal response are similar to ATP. However, the
production of IP3 does not increase during activation of
the P2Y11 receptor by UTP [58].
Dinucleotide polyphosphates activate various subtypes
of P2Y receptors [59] (Fig. 5b). At the P2Y1 receptor,
diadenosine pentaphosphate (Ap5A 70c,E C 50=0.32 μM) is
more potent than ATP (EC50=0.65 μM), and Ap3A 70a
(EC50=0.011 μM) is equipotent to ADP (EC50=0.014 μM)
[60]. However, none of the diadenosine polyphosphates
activate the P2Y11 receptor, with the exception of Ap4A
70b, which increases the level of intracellular [Ca
2+]a ta
concentration of 1 mM [54, 57, 61].
Experiments performed on human P2Y11 receptor-
infected 1321N1 astrocytoma cells indicated increased
intracellular production of IP3 and cyclic AMP followed
by elevation of Ca
2+ induced by nicotinamide adenine
dinucleotide 72 (β-NAD
+) in a concentration range of 1–
100 μM[ 62]. Thus, extracellular β-NAD
+ appears to be an
agonist of the P2Y11 receptor [12]. Moreover, nicotinic acid
adenine dinucleotide phosphate 73 (NAADP
+) also acti-
vates the P2Y11 receptor [63].
Various analogues of ATP 1 have been examined as
potential agonists of the P2Y11 receptor (Fig. 1). The rank
order of agonist potency is ATP > ADP >> AMP =
adenosine in erythroleukemic K562 cells and in acute
monocytic leukemia U937 cells stably transfected with the
P2Y11 receptor (K11 and U11 cells, respectively) [64]. NB4
promyelocytic cells behave similarly [16]. ATP-γ-S 7 is a
more potent P2Y11 receptor agonist than ATP in 1321N1,
CHO-K1, U11, K11, and NB4 cells. Also in U11 and K11
cells, ATP-α-S and ADP-β-S 8 are more potent than ATP.
Interestingly, ADP-β-S produces no agonist effect at the
P2Y11 receptor in NB4 cells [65]. Adenosine 5′-thiomono-
phosphate (α-thio-AMP) is almost inactive at the P2Y11
receptor [64, 65].
BzATP (2′ or 3′-O-(4-benzoyl)benzoyl-ATP) is equipo-
tent to ATP-γ-S in 1321N1, CHO-K1, U11, and NB4 cell
lines. In contrast, in K11 cells, BzATP (EC50=63 μM) is
one of the weakest P2Y11 receptor agonists. Interestingly,
2′-dATP is a more potent agonist of this receptor than ATP
in all these cell lines [54, 57, 64].
Replacement of the α,β-o rβ,γ- o x y g e na t o mb yam e t h -
ylene group decreases the potency of the ligand in comparison
with ATP [64, 65]. Also, 2-MeS-ATP 11 is weaker than ATP at
the P2Y11 receptor subtype expressed in 1321N1, CHO-K1,
and U11 cells but not in K11 cells. In addition, 2-Cl-ATP is a
weak P2Y11 receptor agonist [66]. However, 2-propylthio-β,
γ-dichloromethylene-ATP (AR-C67085, 36, an antagonist of
the P2Y12 receptor) is the most potent reported agonist of the
P2Y11 receptor (EC50=8.9 μM) [57, 67].
The effects of replacement of the ATP ribose moiety by a
(N)- or a (S)-methanocarba-constrained carbocyclic ring
were studied at the human P2Y4 receptor [36]. The potency
of (N)-methanocarba-ATP 21 (EC50=34.5 μM) is equiva-
lent to unmodified ATP (EC50=17 μM). In contrast, (S)-
methanocarba-ATP 22 produces no effect at the P2Y11
receptor at a concentration of 100 μM. It is possible that not
only (N)-methanocarba analogues but also the (N)-confor-
mation of the ribose ring of ATP analogues are preferred at
the P2Y11 receptor. In addition, these data demonstrate that
the oxygen atom of the ATP ribose ring is not essential for
agonist potency.
The preferences of green fluorescent protein (GFP)-tagged
P2Y11 receptor stably expressed in 1321N1 astrocytoma cells
for ATP-α-S and ATP-α-S diastereoisomers were the focus
of recent studies [66]. Rp-ATP-α-S (EC50=0.27 μM) and
Sp-ATP-α-B (EC50=0.34 μM) isomers are more potent than
their respective Sp (EC50=1.71 μM) and Rp (EC50=
2.38 μM) isomers. Moreover, these compounds are more
potent than ATP (EC50=2.83 μM). In addition, both Rp- and
Sp-2-MeS-ATP-α-S (EC50=0.64 and 2.64 μM) are more
potent at the P2Y11 receptor than is 2-MeS-ATP (EC50=
13.8 μM) [66]. Interestingly, for the P2Y1 receptor, these
ligands display the opposite stereoselectivity, but for the P2Y2
and P2Y4 receptors, Rp-UTP-α-S (EC50 P2Y2=5.4μM, EC50
P2Y4=27 μM) is more potent than the Sp-UTP-α-S-
analogue (EC50 P2Y2=14 μM, EC50 P2Y4=81 μM) [16].
Various nonnucleotide derivatives have been shown to
inhibit P2Y11 receptors (Fig. 4). Suramin 48a, a drug used
to treat trypanosomiasis and onchocerciasis, weakly antag-
onizes various P2Y and P2X receptors, and its SAR is
known in detail [52]. Suramin also inhibits G protein
signaling intracellularly. P2Y11 receptor antagonists derived
82 Purinergic Signalling (2009) 5:75–89from suramin exhibit nanomolar potency [68]. NF157 48b
has a pKi value of 7.35 at the P2Y11 receptor and displays
the following selectivity ratios (x-fold) over P2Y1 (>650),
P2Y2 (>650), P2X2 (1), P2X2 (3), P2X3 (8), P2X4 (>22),
and P2X7 (>67) receptors.
ATP derivatives as P2Y2 receptor agonists
The P2Y2 receptor is activated by both uracil and adenine
5′-triphosphates (Fig. 1). The SAR of UTP derivatives at
the P2Y2 receptor are treated separately below.
In contrast to UTP 3, which can activate only P2Y2 and
P2Y4 receptors, ATP 1 is an agonist for three P2Y receptor
subtypes P2Y2 (EC50=0.085 μM), P2Y1 (EC50=1.5 μM),
and P2Y11 (EC50=17.3 μM) [36]. For this reason the
design of ATP analogues with P2Y2 receptor selectivity is a
difficult problem.
BzATP and ATP-γ-S are weaker than ATP, and ATP-α-S
is inactive at the mouse P2Y2 receptor [69, 70]. Substitution
of the α,β-oxygen atom of ATP by a methylene group
(α,β-MeATP) results in a ligand that is virtually ineffective
at the P2Y2 receptor [71]. In addition, replacement of the
β,γ oxygen atom in the 5′-triphosphate chain of ATP by a
β,γ-methylene or β,γ-imido group leads to ligands with no
effect at the P2Y2 receptor at concentration of 1 mM [69,
70]. Although the P2Y1 receptor can be potently activated
by 2-MeS-ATP 11, this ligand is inactive at the P2Y2
subtype. However, 2-Cl-ATP is a weak agonist of the P2Y2
receptor (EC50=2.30 μM). The potency of 8-Br-ATP is
reported to be EC50=23.0 μM[ 72].
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indicatethatattheP2Y2 receptor (N)-methanocarba-ATP (21,
EC50=0.091 μM) and (N)-methanocarba-UTP (62,E C 50=
0.0159 μM) are equipotent to ATP and UTP, respectively. In
contrast, (S)-methanocarba-ATP (22,E C 50=3.7 μM) is
significantly weaker than ATP.
Uracil nucleotide-responsive P2Y receptors
SAR of P2Y2 and P2Y4 receptors for 5′-triphosphates
The most prominent tissues of distribution of these UTP-
responsive receptors are P2Y2 (vascular cells, epithelial cells)
and P2Y4 (gastrointestinalcells,placenta,cochlearcells).These
two receptors display the highest identity in the sequences of
their TM domains (66.8%) of all P2Y receptor subtypes.
Phosphate modifications and dinucleotides The P2Y2 re-
ceptor is activated nearly equipotently by UTP 3 (EC50=
0.049 μM) and ATP 3 (EC50=0.085 μM) (Fig. 1). How-
ever, it is not activated by the 5′-diphosphates UDP 4 and
ADP 2. An early publication showed UDP to be active, but
this was later attributed to the presence of UTP in com-
mercial preparations of UDP [73]. Uridine γ-thiodiphos-
phate (UTP-γ-S) 9 is a selective agonist for P2Y2 (EC50=
0.24 μM) and P2Y4 (EC50=1.6 μM) receptors [43].
The P2Y2 receptor is activated by dinucleotide mole-
cules [72] as well as uracil or adenine triphosphates. The
dinucleotides Up4U (INS365, Diquafosol) 68c and Up4dC
(INS37217, Denufosol) 69 (Fig. 5) have the optimal
phosphate chain length for activation of the P2Y2 receptor
(EC50=0.1 and 0.22 μM) and tend to be more resistant to
degradation by nucleotidases than nucleoside triphosphates
[59, 60]. Up4-[5′]-ribose 74 activates the P2Y2 receptor
with an EC50 of 1.88 μM, i.e., ninefold less potent than
Up4U 68c.U p 4-[5′]-ribose 74 still activates the P2Y2
receptor and serves as a truncated form of Up4U 68c for
purposes of modeling receptor docking [74]. On the other
hand, Up2U 68a, containing only two phosphate groups, is
nearly inactive as an agonist, and Up6U 68d is 98-fold
weaker than Up4U at the P2Y2 receptor.
The model of receptor-docked Up4U is consistent with a
tetraphosphate chain having the optimal length for dinucle-
otide binding [74]. The phosphate side chain of diuridine
diphosphates apparently is too short to allow uridineII to
reach its binding pocket. However, in the case of Up6U, its
phosphate chains are too large to be fully accommodated
inside the receptor. Also, as discussed by Brunschweiger
and Müller [4], among various linear dinucleotides, only
dinucleoside tetraphosphates have the same number of
negatively charged oxygen atoms as UTP.
Ribose and uracil modifications Both 2′-deoxy-2′-amino-
UTP and 2-thio-UTP 63a preserve the agonist potency of
UTP at the P2Y2 receptor (Fig. 5a). Combination of these
two modifications yields 2′-amino-2-thio-UTP, compound
63b, synergizes to enhance both potency (8 nM EC50) and
selectivity (300-fold P2Y2-selective versus P2Y4). 2′-Amine
acetylation reduces potency, and trifluoroacetylation produces
intermediate potency.
Modification at position 5, such as 5-bromo-UTP (EC50=
0.75 μM) and 5-iodo-UTP (EC50=0.83 μM), suggests that
introducing a small hydrophobic group might be beneficial
at the P2Y2 receptor. However, 5-methyl UTP (EC50=
0.48 μM) does not enhance potency, and the 5-amino
(EC50=5.6 μM) and 5-azido (EC50=1.8 μM) analogues are
less potent at the P2Y2.
2′-Deoxy-UTP (EC50=1.08 μM) is 22-fold less potent
than UTP (EC50=0.049 μM); replacement of the 2′-
hydroxyl group by a 2′-methoxy group (EC50=14.3 μM)
reduces the potency further (290-fold weaker than UTP).
Thus, the hydroxyl group at the 2′-position appears to be
important for agonist activities as a donor of H-bonding to
the P2Y2 receptor.
AR-C126313 52 and its higher-molecular-weight ana-
logue AR-C118925 53 are selective antagonists of the P2Y2
receptor [75] (Fig. 4). Recently, flavonoid derivatives, e.g.,
54,[ 76], and derivatives of Reactive Blue 2 46a, such as 1-
amino-4-(2-methoxyphenyl)-2-sulfoanthraquinone (PSB-
716) 46b [77], have been explored as P2Y2 receptor
antagonists. Flavonoid antagonists reduce the amplitude of
the P2Y2 receptor response to UTP but not the EC50 value,
indicating allosteric antagonism [76].
New ligand tools are neededtodistinguish P2Y2 and P2Y4
receptor subtypes pharmacologically and to extend the
characterization of the few existing tools to a wider range
of species. Selective antagonists of the P2Y4 receptor have
not yet been identified. Suramin 48a is more potent as a
competitive antagonist at the human P2Y2 receptor than at
the P2Y4 receptor [4, 5]. The order of potency of agonists is
useful in this regard [16]. 2′-Azido-2′-deoxyUTP 64 is
fivefold more potent in activation of phospholipase C
(PLC0 at the human P2Y4 receptor than at the P2Y2 recep-
tor (EC50=0.54 μM vs. 0.78 μM). 4-Thio-UTP (EC50=
0.023 μM) is 15-fold more potent than 2-thio-UTP (EC50=
0.35 μM) in activating the human P2Y4 receptor.
SAR of P2Y6 receptor for 5′-diphosphates
The major tissue distribution of these UDP-responsive
receptors includes vascular smooth muscle cells, microglial
cells, and neutrophils. This receptor exhibits significant
homology with the TM domains of other P2Y1-like receptors,
such as P2Y1 (43.0%), P2Y2 (47.7%), P2Y4 (48.2%), and
P2Y11 (31.6%).
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S 10 (EC50=47 nM) is more potent than UDP (EC50=
300 nM) in activation of the P2Y6 receptor and is more
stable toward ectonucleotidases. 5-Br-UDP (EC50=800 nM)
and the dinucleotide triphosphate (71, INS48823) are potent
and/or stable agonists of the P2Y6 receptor (EC50=125 nM)
[72, 78] (Figs. 1 and 5). The SAR and molecular modeling of
the uracil nucleotide-activated P2Y6 receptor were investigat-
ed recently [79, 80]. Novel UDP analogues were synthesized
and assayed for activity at the human P2Y6 receptor.
The P2Y6 receptor is generally selective for 5′-diphosphate
derivatives. Thus, uridine 5′-monophosphate, 2′-deoxyuridine
3′,5′-bisphosphate, a cyclic 3′,5′-diphosphate analogue, and a
uridine 3′-diphosphate derivative are inactive as either
agonists or antagonists.
Within a series of uracil dinucleoside 5′,5′-polyphos-
phates, the triphosphates (68b and 71) are the most potent
and selective (EC50=0.2 and 0.125 μM). The simple Up2U
68a displays low potency at the P2Y6 receptor.
Modification of ribose hydroxyl groups of UDP has
not yielded more potent P2Y6 receptor agonists. Substi-
tution with a 2′-azido or 2′-amino group reduces potency
at the P2Y6 receptor. Removal of either the 2′-o r3 ′-
hydroxyl group of UDP yields a >100-fold decrease in
potency. The (S) conformation of the ribose moiety is
preferred for ligand recognition by the P2Y6 receptor [79].
A UDP derivative locked in the (N) conformation by an
(N)-methanocarba ring is completely inactive, and the 2′-
deoxy-(S)-methanocarba derivative 67 is moderately po-
tent in activating the P2Y6 receptor (Fig. 5A ) .T h i si sa
rare example of the use of molecular modeling to predict
the conformational preference in a putative GPCR binding
site for rational ligand design. The computational predic-
tion led to the subsequent synthesis of a novel analogue
containing a rigid carbocyclic ribose substitute that is
more potent than the corresponding 9-(2′-deoxyriboside)
as a P2Y6 agonist.
The uracil ring was modified at the 2-, 3-, 4-, and 5-
positions. Modification at the 3-position with N-CH3
markedly decreases potency, but halogenation of the 5-
position in the iodo analogue 66 (Fig. 5A) yields a molecule
that is equal in potency (EC50=0.15 µM) to UDP and is
similar in potency to a 5-bromo analogue previously reported
to be roughly equipotent to UDP [80]. A 5-iodo modification
maintains potency at the P2Y6 receptor, and 5-halo substi-
tution of the uracil ring may therefore provide a basis for
achieving selectivity at this subtype. In a series of uracil-
modified compounds, 2-thio-UDP (EC50=0.06 μM) and 4-
thio-UDP (EC50=0.08 μM) are five- to six-fold less potent
than UDP. 4-Thioether derivatives and 4-carboxyalkylthio
derivatives exhibit lower potency than the parent compound
4-thio-UDP. 3-Phenacyl-UDP 65 (EC50=70 nM) is a potent
and selective P2Y6 receptor agonist [81].
Only one class of antagonists of the P2Y6 receptor has
been reported. The diisothiocyanate derivative MRS2578
55 (EC50=0.037 μM) is a potent, insurmountable antago-
nist of P2Y6 nucleotide receptors [82] (Fig. 4). Related
compounds 56 and 57 have varied selectivity for P2Y
receptor subtypes. These isothiocyanate derivatives likely
bind covalently to P2Y receptors; they are hydrophobic and
have limited stability in aqueous solution.
SAR of P2Y14 receptor for UDP-sugars
The most atypical P2Y receptor is the P2Y14 receptor, which
is distributed in the immune system, including in dendritic
cells and the central nervous system. The identity of amino
acid residues of TM domains of the P2Y14 receptor with
P2Y12 and P2Y13 subtypes is 57.0% and 52.8%, respectively.
However, in contrast to other P2Y receptors, the P2Y14
receptor is not activated by uridine 5′-di- or triphosphates or
by adenine nucleotides [83]. The P2Y14 receptor is the only
subtype to respond principally to UDP-glucose 5 (EC50=
0.35 μM) and other UDP-sugars, such as UDP-glucuronic
acid 75 (EC50=102 nM), and the endogenous nucleotides
UDP-galactose 76 (EC50=0.67 μM) and UDP-N-acetylglu-
cosamine 77 (EC50=4.38 μM) (Fig. 5C). The SAR of
analogues of UDP-glucose at the P2Y14 receptor was recently
systematically explored [84]. Novel analogues modified on
the nucleobase, ribose moiety, and glucose moieties were
synthesized and characterized biologically at the recombinant
human P2Y14 receptor.
The P2Y14 receptor appears to be the most restrictive of
the P2Y family with respect to modification of the nucleo-
base, ribose, and phosphate moieties. Most of the novel
analogues of 5 modified on the uracil or ribose moieties are
inactive. All compounds modified at the 5-position of uracil
moiety (i.e., with azido, amino, and iodo) or at the 2′,3 ′
hydroxy groups of ribose ring are inactive. Analogues with
other nucleosides, such as adenosine, guanosine, cytidine,
thymidine, deoxyuridine and deoxycytidine, are inactive. The
dinucleotides Up2U 68a and Up4U 68c are inactive at the
P2Y14 receptor.
Among the analogues of 5, a 2-thiouracil analogue,
MRS2690 78, is tenfold more potent (EC50=49 nM). A 4-
thiouracil (EC50=0.29 μM) analogue is equipotent to 5, but
a 4-methyl-4-thiouracil moiety is not tolerated. The 2- and
4-thio modifications preserve potency at all uracil nucleo-
tide-responsive subtypes but most effectively at the P2Y2
and P2Y4 receptors.
The high potency of analogues 75 (UDP-glucuronic acid)
and 76 (UDP-galactose) suggests a flexibility of structural
modification at the glucose C4 and C6 positions. The 12-
fold-lower potency of 77 (UDP-N-acetylglucosamine) in com-
parison with 5 suggests a limited tolerance for steric bulk at
the glucose C2 position. Modification of the glucose moiety
Purinergic Signalling (2009) 5:75–89 85of 5 to yield, for example, UDP-fructose, UDP-mannose, and
UDP-inositol, preserved agonist potency at the P2Y14
receptor, as predicted in a modeling study [85].
Conclusion
The medicinal chemistry of several of the P2Y receptors has
recently acquired detailed qualitative and quantitative SARs.
Selective agonists (for P2Y1,P 2 Y 2,a n dP 2 Y 6 receptors) and
selective antagonists (for P2Y1,P 2 Y 2,P 2 Y 6,P 2 Y 11,P 2 Y 12,
and P2Y13 receptors) have been identified. At the P2Y1 and
P2Y12 receptors, 5′-diphosphate agonist derivatives have
been transformed into potent and selective antagonists by
alteration of the phosphate moieties and nucleobase and
substitution pattern and introduction of carbocyclic substitu-
tion of the ribose moiety. Empirical and computational
methods have identified conformations of the ribose moiety
that enhance affinity at the P2Y1 and P2Y6 receptors have
been identified through—and these conformations have been
chemically locked to provide novel—selective ligands.
Screening of chemically diverse compound libraries has
begun to yield new lead compounds for the development of
P2Y receptor antagonists, e.g., directly acting P2Y12 receptor
antagonists with antithrombotic activity. Challenges remain-
ing include identification of selective agonists for the P2Y4,
P2Y11,a n dP 2 Y 13 receptors and of selective antagonists for
the P2Y4 and P2Y14 receptors. The discovery of new,
selective P2Y receptor ligands and optimization of existing
structural leads hold promise for the identification of new
clinical agents that exploit nucleotide receptor signalling.
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